Skip to content
Back to MYGN

Myriad Genetics Inc

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 17, 2025
Transactions
6
Purchases
5
Sales
1
Purchase value
$722.20K
Sale value
$66.84K

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Rashmi KumarDirector
4Rule 10b5-1 plan disclosed
Filed Jun 9, 2026Period of report Jun 8, 20260001824720-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 8, 2026
Common StockF1F215,000$4.4562$66.84K171,889Direct
Filing footnotes · 2
  1. F1The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.37 to $4.63, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Paul BisaroDirector
4
Filed May 14, 2026Period of report May 14, 20260001237253-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMay 14, 2026
Common Stock7,500$3.685$27.64K97,441Direct
Open on SEC EDGAR
Samraat S. RahaDirector · President and CEO
4
Filed Mar 9, 2026Period of report Mar 9, 20260001738340-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMar 9, 2026
Common StockF140,000$4.9961$199.84K493,104Direct
Filing footnotes · 1
  1. F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.97 to $5.00, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
S. Louise PhanstielDirector
4
Filed Feb 27, 2026Period of report Feb 25, 20260001471518-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseFeb 27, 2026
Common StockF348,000$4.661$223.73K281,951Direct
PurchaseFeb 26, 2026
Common StockF250,407$4.803$242.10K233,951Direct
PurchaseFeb 25, 2026
Common StockF16,100$4.736$28.89K183,544Direct
Filing footnotes · 3
  1. F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.725 to $4.75, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  2. F2The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.71 to $5.01, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  3. F3The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.51 to $4.79, inclusive. The reporting person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.